Each year the RDTC considers the information published in the SPS Prescribing Outlook series, and from this information highlights developments that are likely to have significant impact on primary care prescribing budgets, over the coming 12 – 15 months.

This is supplemented throughout the year with the RDTC Monthly Horizon Scanning series, which provides a more accurate monthly account of the impact of new medicines and recommendations as they publish.

The Annual Horizon Scanning report highlights relevant national guidance and policies, expected cost pressures, and anticipated risks.

This document was revised in March 2024 following publication of the rimegepant for acute migraine NICE resource impact template.

This publication is part of our Strategic Support and Planning contract. To gain access please email us at nuth.nyrdtc.rxsupp@nhs.net.